trametinib and dabrafenib

Trametinib is an antineoplastic agent indicated as a single agent for the treatment of treatment-naïve patients with BRAF V600E or V600K-mutated unresectable or metastatic melanoma as tested in an FDA-approved trial. When used in combination with dabrafenib, it is indicated for: 1. Treatment of patients with unresectable or metastatic melanoma whose BRAF V600E or V600K mutations have been detected in an FDA-approved test. 2. Adjuvant therapy for patients with melanoma with BRAF V600E or V600K mutations and involved lymph nodes after complete resection based on an FDA-approved test. 3. Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose BRAF V600E mutation has been detected in an FDA-approved trial. 4. Treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) who have BRAF V600E mutations and no satisfactory locoregional treatment options. 5. Treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic BRAF V600E-mutant solid tumors who have progressed after prior therapy and for whom satisfactory alternative treatment options are not available. This indication received accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and characterization of clinical benefit in confirmatory trials. 6. Treatment of pediatric patients 1 year of age and older with BRAF V600E-mutated low-grade glioma (LGG) who require systemic therapy.

The recommended dose of trametinib in the instructions is 2 mg once daily (used in combination with dabrafenib). Continue treatment for 1 year or until disease progression or unacceptable toxicity occurs. The recommended dosage of dabrafenib in the instructions is 150 mg orally, twice a day, about 12 hours apart, as a single drug or in combination with trametinib, at least 1 hour before a meal or 2 hours after a meal. Do not open, crush or destroy the capsule. When co-administered with trametinib, give this product at the same time every day or in the morning or evening, and take trametinib at the same time every day. When trametinib is used in combination with dabrafenib, conduct dermatological evaluation every 2 months during treatment and continued for 6 months after discontinuation of combination therapy. Monitor for signs and symptoms of new noncutaneous malignancies. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.